Buyers of Zetia seek class recertification after 4th circ ruling

Wholesale buyers of MSD’s (known as 'Merck & Co' in the US) cholesterol treatment Zetia have asked a Virginia court to recertify their class status and move to trial following a recent fourth circuit ruling that reversed the court’s prior certification.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Generics

Virginia judge says court should deny class cert in Zetia antitrust suit

27 January 2022 A Virginia district court judge has recommended that buyers of cholesterol drug Zetia should not be granted class certification in pay-for-delay litigation against MSD and Glenmark Generics.

Americas

Zetia buyers secure backing for ‘market narrowing’ in MSD antitrust case

4 November 2021 Wholesale buyers of the cholesterol treatment Zetia have won the backing of a US judge for their market definition in an antitrust suit against MSD and Glenmark.

Americas

MSD and Glenmark appeal pay-for-delay Zetia dispute

7 January 2021 Pharmaceutical companies MSD and Glenmark have argued that the class certification of wholesale buyers of cholesterol drug Zetia should be reversed because the circumstances of the class members do not justify an award of class status.

More on this story

Generics

Virginia judge says court should deny class cert in Zetia antitrust suit

Americas

Zetia buyers secure backing for ‘market narrowing’ in MSD antitrust case

4 November 2021 Wholesale buyers of the cholesterol treatment Zetia have won the backing of a US judge for their market definition in an antitrust suit against MSD and Glenmark.

Americas

MSD and Glenmark appeal pay-for-delay Zetia dispute

More on this story

Generics

Virginia judge says court should deny class cert in Zetia antitrust suit

Americas

Zetia buyers secure backing for ‘market narrowing’ in MSD antitrust case

4 November 2021 Wholesale buyers of the cholesterol treatment Zetia have won the backing of a US judge for their market definition in an antitrust suit against MSD and Glenmark.

Americas

MSD and Glenmark appeal pay-for-delay Zetia dispute